Scarica l'app Stockscreener
5.16
2.79%
0.14
Dopo l'orario di chiusura:
5.16
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
What makes Entrada Therapeutics Inc. stock price move sharplyTrading Opportunities Forecast by AI Insight - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.Swing Entry Risk Mitigation with Chart Analysis - Newser
Measuring Entrada Therapeutics Inc.’s beta against major indicesBuy and Hold Position Summary Review - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - 富途牛牛
Real time breakdown of Entrada Therapeutics Inc. stock performanceTechnical Screener for High Growth Stocks - Newser
HC Wainwright Issues Pessimistic Outlook for TRDA Earnings - Defense World
Published on: 2025-08-11 01:04:23 - Newser
Roth Capital Issues Pessimistic Forecast for TRDA Earnings - Defense World
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
William Blair Issues Negative Forecast for TRDA Earnings - Defense World
Is Entrada Therapeutics Inc. stock reversal real or fakePredictable Income Summary for Long-Term Trades - Newser
Tools to assess Entrada Therapeutics Inc.’s risk profileFree Low Risk Buy Zone Opportunity Watch - Newser
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Stock Picks with Trend Confidence - Newser
Entrada Therapeutics Inc. recovery potential after sell offFree Price Action Based Buy Opportunity List - Newser
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - uk.finance.yahoo.com
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens - MarketScreener
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - Stock Titan
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics - TipRanks
Can volume confirm reversal in Entrada Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
Pattern Scan Adds Entrada Therapeutics Inc. to WatchlistTrade Timing Strategy With Technical Data Explained - metal.it
What drives Entrada Therapeutics Inc. stock priceDiscover market opportunities with real-time data - Jammu Links News
How strong is Entrada Therapeutics Inc. company’s balance sheetAchieve rapid portfolio appreciation today - Jammu Links News
What institutional investors are buying Entrada Therapeutics Inc. stockBreakout profit opportunities - Jammu Links News
Does Entrada Therapeutics Inc. stock perform well during market downturnsAccess powerful market insights for free - Jammu Links News
New Product Launches: Will They Boost Entrada Therapeutics Inc. Stock in 2025Free Conservative Long Term Growth Plans - Newser
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):